INSTITUTIONAL GUIDANCE

1. Is the Office of Sponsored Programs reviewing/approving Clinical Trial Agreements at this time?  
Yes, COVID-19 related projects are receiving priority.

2. Is the Clinical Trials Office reviewing clinical trials at this time?  
Yes, COVID-19 related projects are receiving priority. Study teams should evaluate how illness and absences, drug shortages, facility closures, or lack of required personal protective equipment may impact treatment delivery or monitoring before submitting new studies.

3. Has a written policy been circulated disallowing the recruitment of research patients at this time?  
Yes—Recruitment activities that require face-to-face contact have been paused with the exception of protocols focused on COVID-19, protocols in which there are limited or no treatment alternatives, and emergency use treatment protocols. Recruitment activities that do not require face-to-face interactions may continue. See VPR updates posted on our website for additional guidance: https://wp.uthscsa.edu/coronavirus/university-measures/research/

4. Has the institution placed non-essential research protocols on hold for the foreseeable future (1 month, 3 months, etc.)?  
Continuation of the following types of studies with face-to-face interactions is deemed appropriate: therapeutic research wherein there are limited/no treatment alternatives, FDA "Treatment" or "Emergency Use" studies, studies in which interruption/delay of research could cause significant harm to current research subjects. All other protocols that require face-to-face contact are required to be paused. Research protocols and activities that do not involve face-to-face interactions may continue. See VPR updates posted on our website for additional guidance: https://wp.uthscsa.edu/coronavirus/university-measures/research/

5. Are the ancillary staff needed to conduct the study (pharmacy, dialysis staff, etc.) working onsite on research projects at this time?  
Yes, however illness and absences, drug shortages, facility closures, and lack of required personal protective equipment may have an impact on delivery of these services.

6. Will the institution’s policy on remote monitoring/access to electronic Medical Records be revised in light of travel restrictions and limited onsite visits to hospitals?  
Yes – All visits to UT Health San Antonio facilities unrelated to patient care are indefinitely paused until further notice. This policy applies to in-person study monitoring visits. Currently, remote access to our electronic medical record (EMR) by sponsor’s monitors to verify data accuracy is not possible. See additional information and updated guidance here: https://wp.uthscsa.edu/coronavirus/university-measures/research/

UTHSA IRB GUIDANCE

1. What if a participant is unable to make it for a research study visit?  
If a participant at a site is unable to complete a required study related activity per the IRB approved protocol, this is a protocol departure. Protocol departures that are minor in nature (subjects rights, safety, or welfare are not adversely affected or possibly adversely affected) and are outside of the control of the investigator are considered deviations and do not require prompt reporting to the IRB. Document the deviation in a tracking log and summarize and report the deviation at the time of the study’s continuing review.
2. **How will protocol violations be handled at this time?**
   Protocol violations are departures that are under the control of the investigator and adversely affect the subjects' rights, safety, or welfare. Violations require prompt reporting in accordance with the UTHSA IRB's [Noncompliance Policy](http://research.uthscsa.edu/irb/NoncompliancePolicy). The [Decision Tree - Evaluating Departures](http://research.uthscsa.edu/irb/DecisionTree) may help in determining whether protocol departures require prompt reporting.

3. **Can study procedures be modified to address the impacts of COVID-19?**
   Yes, addressing the impact of COVID-19 may result in some departures being required to eliminate an immediate risk to subjects or others. More information on what changes can be made and when to notify the UTHSA IRB may be found here: [http://research.uthscsa.edu/irb/COVID.pdf](http://research.uthscsa.edu/irb/COVID.pdf)

4. **Does UTHSA have additional safeguards in place for patient participation in research studies in light of the Coronavirus pandemic?**
   Yes - posted on our website here: [http://research.uthscsa.edu/irb/COVID.pdf](http://research.uthscsa.edu/irb/COVID.pdf)

5. **What is your IRB’s contingency plan for IRB review and approval for continuing renewals?**
   The UTHSA IRB is conducting all business activities through remote means, including conducting the continuing review and approval of ongoing human subjects research, where applicable.

6. **Am I required to obtain IRB approval of a notification document informing subjects about remote visits or changes to hospital policies on COVID-19 screening?**
   No - The IRB recommends notifying subjects of the halting of study procedures, changes to study visits, etc. by appropriate means of communication for the patient populations. Document when the notification was made and the method used to notify subjects in the subject’s research record.

7. **Does a Sponsor memo describing a halt in enrollment procedures or an investigators voluntary halt of study related activities need to be reviewed/approved by the IRB through the amendment process?**
   No - These changes can be communicated to the IRB by sending an email to IRBM@uthscsa.edu and including: the protocol number, PI Name, and date voluntary halt was initiated.

---

**EXTERNAL IRB GUIDANCE**

1. **Should I follow local UTHSA IRB guidance for external IRB studies?**
   No – Follow guidance provided by the IRB of record for that particular study and any posted institutional guidance located on our website: [https://wp.uthscsa.edu/coronavirus/university-measures/research/](https://wp.uthscsa.edu/coronavirus/university-measures/research/)

   - Advarra IRB COVID-19 Guidance
   - Brany IRB COVID-19 Guidance
   - Sterling IRB COVID-19 Guidance
   - WIRB COVID-19 Guidance